Exenatide vs Semaglutide
Community accounts comparing exenatide and semaglutide for weight loss — first vs second generation GLP-1, dosing differences, and why most users switched.
0 anonymous reports
We're collecting more reports on this topic.
Submit yourscommunity guides:
Community Q&A
- What is the difference between exenatide and semaglutide?
- Community accounts that address both describe them as GLP-1 receptor agonists from different generations with meaningfully different profiles. Exenatide (Byetta, Bydureon) is a first-generation GLP-1 agonist — shorter half-life, more frequent dosing requirement, and accounts consistently describe it as producing less weight loss than semaglutide at the doses typically encountered. Semaglutide is a newer, more potent GLP-1 agonist with a longer half-life supporting weekly dosing, and community accounts describe dramatically stronger appetite suppression and weight loss outcomes. The account framing: exenatide largely disappeared from community discussions once semaglutide became widely available, except in accounts from users already established on exenatide for diabetes management.
- Is semaglutide more effective than exenatide for weight loss?
- Community accounts that compare both give semaglutide a clear advantage for weight loss. The most common framing in switch accounts: users who transitioned from exenatide to semaglutide describe noticeably stronger appetite suppression and faster weight loss on semaglutide. Accounts from users who trialled exenatide specifically for weight loss before semaglutide was accessible describe more modest outcomes — meaningful but substantially less dramatic than semaglutide accounts for the same time period. The clinical trial data that surfaces in more research-aware accounts aligns with community experience: semaglutide produces roughly 2–3× the weight loss of exenatide at their respective standard doses.
- Who uses exenatide in the peptide community today?
- Exenatide accounts in the archive are almost entirely from two groups: users already established on exenatide for type 2 diabetes management who are sharing experiences alongside other peptide use, and a small subset of early adopters from before semaglutide's widespread availability who describe comparing first- and second-generation GLP-1 options. New-to-GLP-1 accounts starting after 2021 almost universally describe beginning with semaglutide rather than exenatide. Exenatide does appear occasionally in accounts from users who had adverse reactions to semaglutide's nausea and describe exenatide's shorter half-life as allowing faster clearance — the logic being that if a dose causes significant nausea, exenatide clears faster than once-weekly semaglutide.
- What are the side effect differences between exenatide and semaglutide?
- The side effect profiles are broadly similar — nausea, appetite suppression, occasional GI distress — but community accounts describe meaningful practical differences. Exenatide's shorter half-life means nausea from a dose resolves faster; accounts that describe trying exenatide for tolerability reasons specifically cite this. Semaglutide's week-long persistence means that significant nausea from a dose can last days rather than hours. On the other hand, semaglutide accounts more frequently describe adapting to side effects over time and then not needing to manage them — the longer half-life normalises. Accounts switching from exenatide to semaglutide who describe the transition as difficult usually attribute it to the unfamiliarity of persistent appetite suppression rather than more severe nausea per se.